DFE Pharma has announced the launch of EcoLact 2030, a pioneer initiative that is designed to bring transparency and verified sustainability to its current lactose offering.
EcoLact 2030 is designed to provide pharmaceutical manufacturers access to auditable CO2 data and full value-chain traceability, enabling them to demonstrate Scope 3 emission reductions without operational disruption.
Pharmaceutical companies face increasing pressure to meet current climate and ESG targets, particularly when addressing Scope 3 emissions (all indirect emissions, except for purchased energy, that occur in the value chain).
These are often very difficult to quantify due to limited transparency and inconsistent data quality.
EcoLact 2030 addresses this gap by providing primary, traceable emission data of an accelerated 30% CO2 reduction across DFE Pharma’s lactose portfolio, without relying on offsets or estimates.
This CO2-verification offering is backed by granular data and performance-based sustainability incentives for farmers.
DFE Pharma’s lactose excipients verified with EcoLact 2030 remain unchanged in terms of quality, performance and regulatory compliance, so manufacturers can achieve their sustainability goals without additional product requalification steps.
Companies using EcoLact 2030-verified lactose receive annual CO2 reduction reports to support their Corporate Sustainability Reporting Directive (CSRD), Science Based Targets initiative (SBTi) and ESG reporting.
"EcoLact 2030 reflects our commitment to lead in sustainable sourcing without compromising the quality our customers rely on," said Sven Abend, CEO of DFE Pharma.
"By providing verified data and transparent practices, we enable measurable progress toward climate goals while securing the operational continuity of our customers."